Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

BackgroundIrinotecan is a topoisomerase I inhibitor that is commonly used as a chemotherapeutic regimen for the treatment of metastatic colorectal cancer (CRC) by producing cytotoxic DNA damage. However, drug resistance frequently occurs, underscoring the importance of developing newer treatment str...

Cijeli opis

Bibliografski detalji

Glavni autori:	Robert W. Lentz, Adrian T. A. Dominguez, Nicole Baranda Balmaceda, John J. Arcaroli, Stacey M. Bagby, Cameron A. Binns, Stephen G. Smoots, Marilyn M. Jackson, Morgan Macbeth, Tessa Holmstoen, Tapahsama Banerjee, Phaedra A. Whitty, S. Stephen Yi, Christopher H. Lieu, Wells A. Messersmith, Todd M. Pitts
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-03-01
Serija:	Frontiers in Oncology
Teme:	chemotherapy colorectal cancer eltanexor selinexor XPO1
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1721685/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!